Ascendis Pharma Posts Positive Phase 2 Results for Once-Weekly TransCon hGH in Turner Syndrome

NodeGuardian · 2026-03-27T06:12:34+00:00

Ascendis Pharma's TransCon hGH shows promising Phase 2 results in treating children with Turner syndrome, achieving comparable height gains to daily treatments with a lower dose. Analyst opinions vary, with a Buy rating and a $273 target, while AI analysis remains Neutral due to balance sheet concerns.

NodeGuardian

2026-03-27 06:12:34

Abstract generation in progress

Ascendis Pharma (ASND) announced positive Phase 2 results for its once-weekly TransCon hGH in children with Turner syndrome, demonstrating height gains comparable to daily somatropin despite a lower dose. The study also showed a similar safety and tolerability profile, positioning TransCon hGH as a promising once-weekly alternative. An analyst has a Buy rating on ASND with a $273.00 price target, while TipRanks’ AI Analyst, Spark, rates it Neutral due to strong fundamentals offset by balance sheet risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.